<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We evaluated a newly developed enzymeimmunoassay for serum erythropoietin (Epo) and investigated relationship between Epo levels and <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disorders</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>This method has several advantages including simplicity, high sensitivity, good precision </plain></SENT>
<SENT sid="2" pm="."><plain>Moreover, the procedure requires only about 2.5 hours </plain></SENT>
<SENT sid="3" pm="."><plain>Samples from 134 healthy subjects showed a <z:mpath ids='MPATH_458'>normal</z:mpath> logarithmic distribution, and its <z:mpath ids='MPATH_458'>normal</z:mpath> range was 4.5 approximately 21.3 mU/ml </plain></SENT>
<SENT sid="4" pm="."><plain>The levels of Epo in <z:mpath ids='MPATH_458'>normal</z:mpath> subjects and various <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disorders</z:e> were as follows: 10.5 +/- 4.1 (mean +/- SD mU/ml) in <z:mpath ids='MPATH_458'>normal</z:mpath> subjects, 2.2 +/- 1.7 in <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>), 6.1 +/- 3.1 in <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythemia</z:e>, 17.8 +/- 27.3 in <z:hpo ids='HP_0011010'>chronic</z:hpo> myelogeneous <z:hpo ids='HP_0001909'>leukemia</z:hpo>, 3.6 +/- 1.8 in stress <z:hpo ids='HP_0001901'>erythrocytosis</z:hpo>, 39.4 and 14.1 in two cases of primary <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo>, 1289 +/- 4798 in <z:hpo ids='HP_0001891'>iron deficiency anemia</z:hpo> and 6564 +/- 10870 in <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>In patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>, serum Epo were low and did not correlate with <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> concentration </plain></SENT>
<SENT sid="6" pm="."><plain>However, inverse correlation was found between changes of Epo levels and <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> levels in most patients </plain></SENT>
<SENT sid="7" pm="."><plain>In cases in which <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> progressed into <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo>, <z:hpo ids='HP_0001903'>anemia</z:hpo> developed and Epo levels increased accordingly </plain></SENT>
<SENT sid="8" pm="."><plain>These results suggest that the method is thought to be useful and reliable for the diagnosis and monitoring of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> and related <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disorders</z:e> </plain></SENT>
</text></document>